Capital Advisors Ltd. LLC Buys 978 Shares of Pfizer Inc. (NYSE:PFE)

Capital Advisors Ltd. LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,836 shares of the biopharmaceutical company’s stock after purchasing an additional 978 shares during the quarter. Capital Advisors Ltd. LLC’s holdings in Pfizer were worth $427,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of PFE. Atwater Malick LLC raised its stake in shares of Pfizer by 1.2% during the third quarter. Atwater Malick LLC now owns 165,839 shares of the biopharmaceutical company’s stock worth $5,501,000 after acquiring an additional 1,964 shares in the last quarter. Newbridge Financial Services Group Inc. raised its stake in shares of Pfizer by 21.2% during the third quarter. Newbridge Financial Services Group Inc. now owns 14,506 shares of the biopharmaceutical company’s stock worth $481,000 after acquiring an additional 2,534 shares in the last quarter. Willis Investment Counsel raised its stake in shares of Pfizer by 4.6% during the third quarter. Willis Investment Counsel now owns 1,070,451 shares of the biopharmaceutical company’s stock worth $35,507,000 after acquiring an additional 47,517 shares in the last quarter. Berkshire Money Management Inc. raised its stake in shares of Pfizer by 3.5% during the third quarter. Berkshire Money Management Inc. now owns 22,263 shares of the biopharmaceutical company’s stock worth $738,000 after acquiring an additional 750 shares in the last quarter. Finally, Farmers & Merchants Trust Co of Chambersburg PA raised its stake in shares of Pfizer by 3.5% during the third quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 34,283 shares of the biopharmaceutical company’s stock worth $1,137,000 after acquiring an additional 1,165 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on PFE. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Finally, Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.81 during trading on Thursday, reaching $25.46. 19,799,717 shares of the company traded hands, compared to its average volume of 41,588,910. The firm has a 50 day simple moving average of $27.05 and a 200-day simple moving average of $28.50. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $144.17 billion, a PE ratio of 71.14, a P/E/G ratio of 1.19 and a beta of 0.61. Pfizer Inc. has a 52-week low of $25.23 and a 52-week high of $40.37.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter last year, the firm posted $1.14 EPS. The business’s quarterly revenue was down 41.3% compared to the same quarter last year. Equities research analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.60%. Pfizer’s payout ratio is 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.